We take a look at the main M&A transactions in the Spanish pharmaceutical sector in 2017. In addition, we analyse the purchase of Anota, specialised in distribution for pharmacies and orthopaedics, by Grupo Prim for €1.23M.
We take a look at the main M&A transactions in the Spanish pharmaceutical sector in 2017. In addition, we analyse the purchase of Anota, specialised in distribution for pharmacies and orthopaedics, by Grupo Prim for €1.23M.
About Anota
Anota is a company dedicated to the design, development, manufacture and distribution of technical aids and sports medicine products in the pharmacy and orthopaedic channel in the area of orthotics, podiatry, therapeutic compliance systems and technical aids.
Founded in 1990 with headquarters in Sabadell and offices in Barcelona and Madrid, the company achieved a turnover of €3.2M last year.
About Prim
Prim is a privately owned Spanish business group listed on the Madrid Stock Exchange since 1985. The Group is a reference in the hospital and orthopaedic supplies market, in physiotherapy, thalassotherapy, thermalism, spa, rehabilitation, geriatrics and technical aids. Its activity is divided into six divisions: Hospitals, Orthopaedics, Orthopaedic Clinics, Physiotherapy and Rehabilitation, Pharma and Spa.
It is the leading supplier of healthcare products and services in the Spanish market, with more than 22,000 references in its product portfolio. The Prim Group closed the last financial year with an increase in turnover of 11%, reaching €110.1M, with a net profit of €11.26M (compared to €10.7M in 2015) and a margin on sales of 10.24%. Its ebitda was €15M, 12.7% higher than in 2016, and its financial debt was also reduced by 24.4% last year, with a volume of €1.6M.
Prim acquires distributor Anota for €1.23m
Prim, a company dedicated to the supply of hospital and orthopaedic devices, has acquired the distribution company for pharmacies and orthopaedics Anota for €1.23m. The transaction will be supplemented by a variable portion that will be subject to the results of the acquired company between 2019 and 2021.
This operation reinforces the Prim Group's presence in this channel, allowing it to continue to make progress in its growth strategy within the healthcare sector, thanks to the complementary nature of the structures of the two companies in operational terms, as well as in terms of their distribution and sales network and their range of products.
